- Home
- ASPI vs VERV Comparison
ASPI vs VERV Comparison
Compare ASPI & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- VERV
- Stock Information
- Founded
- ASPI 2021
- VERV 2018
- Country
- ASPI United States
- VERV United States
- Employees
- ASPI N/A
- VERV N/A
- Industry
- ASPI Major Chemicals
- VERV Medicinal Chemicals and Botanical Products
- Sector
- ASPI Industrials
- VERV Health Care
- Exchange
- ASPI Nasdaq
- VERV Nasdaq
- Market Cap
- ASPI 470.6M
- VERV 384.2M
- IPO Year
- ASPI 2022
- VERV 2021
- Fundamental
- Price
- ASPI $7.57
- VERV $11.06
- Analyst Decision
- ASPI Strong Buy
- VERV Buy
- Analyst Count
- ASPI 2
- VERV 9
- Target Price
- ASPI $7.75
- VERV $14.75
- AVG Volume (30 Days)
- ASPI 4.6M
- VERV 7.8M
- Earning Date
- ASPI 08-18-2025
- VERV 08-07-2025
- Dividend Yield
- ASPI N/A
- VERV N/A
- EPS Growth
- ASPI N/A
- VERV N/A
- EPS
- ASPI N/A
- VERV N/A
- Revenue
- ASPI $4,405,477.00
- VERV $59,613,000.00
- Revenue This Year
- ASPI $512.64
- VERV $27.75
- Revenue Next Year
- ASPI $181.15
- VERV N/A
- P/E Ratio
- ASPI N/A
- VERV N/A
- Revenue Growth
- ASPI 245.97
- VERV 271.44
- 52 Week Low
- ASPI $1.86
- VERV $2.87
- 52 Week High
- ASPI $10.08
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- ASPI 48.06
- VERV 84.74
- Support Level
- ASPI $7.55
- VERV $5.88
- Resistance Level
- ASPI $8.12
- VERV $11.41
- Average True Range (ATR)
- ASPI 0.75
- VERV 0.49
- MACD
- ASPI -0.21
- VERV 0.64
- Stochastic Oscillator
- ASPI 20.32
- VERV 95.00
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.